Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Doko MD is an online telehealth service for patients in the United States, with a focus on diabetes management, CGM guidance, A1C goal planning, prescription renewals, non-emergency consultations, medical weight loss, and ongoing follow-up. Its website emphasizes online assessments provided by licensed clinical professionals and supports diabetes and weight-loss services across the U.S.
Based on the main content, Doko MD is not a traditional enterprise SaaS product, but rather a “medical service + online workflow” model. For diabetes care, it includes blood glucose/CGM trend interpretation, A1C goal management, medication reviews, nutrition education, and insurance eligibility guidance for diabetes supplies and CGMs. For weight loss, it offers Semaglutide and Tirzepatide, including online consultations, baseline bloodwork, medication and supply delivery, and dosage follow-up. The platform also covers Urgent Care, men’s health/ED, remote monitoring, and multilingual communication support.
Pricing for the weight-loss program is relatively transparent: Semaglutide starts at $125/month and goes up to $395/month; Tirzepatide starts at $185/month and goes up to $599/month. The page states that pricing includes medication, supplies, consultations, baseline bloodwork, and delivery, with no hidden fees, and that no insurance is required to get started. Specific pricing for the diabetes program and urgent consultations is not disclosed. Whether supplies/CGMs are available at $0 cost depends on insurance, clinical review, and eligibility.
The main advantage is its relatively integrated care pathway, bringing diabetes care, metabolic health, nutrition education, and weight-loss follow-up into one system. Its weight-loss pricing and dosage tiers are transparent. It also highlights HIPAA Secure and SSL Protected, which are basic compliance signals for a healthcare setting. The drawbacks are that the website does not disclose SaaS capabilities such as APIs, third-party system integrations, backend permissions, enterprise management, mobile apps, or data export. Patient reviews mainly come from the official website, with limited external validation. Some service outcomes also depend on insurance and clinical review.
Doko MD is suitable for U.S. patients seeking remote diabetes follow-up, CGM data interpretation, medication reviews, nutrition management, and GLP-1 weight-loss treatment. If an enterprise buyer is looking for a healthcare SaaS product that can be integrated into internal systems, the currently available public information is insufficient to support technical selection.
Access from mainland China is not mentioned in the main content, and domain connectivity is unknown. Even if the site is accessible, its services are clearly designed around the U.S. healthcare, prescription, and insurance systems, making it of limited practical relevance to users in China.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on doko.md official site.
doko.md is an United States SaaS provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach doko.md directly.